William Guyer - 01 Mar 2023 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role
Chief Development Officer
Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer.
Issuer symbol
CORT
Transactions as of
01 Mar 2023
Net transactions value
+$29,234
Form type
4
Filing time
03 Mar 2023, 17:52:12 UTC
Previous filing
06 Sep 2022
Next filing
06 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Award $29,234 +1,472 +80% $19.86 3,316 01 Mar 2023 Direct F1, F2, F3
transaction CORT Common Stock Award $0 +1,472 +44% $0.000000 4,788 01 Mar 2023 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2023.
F2 In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F3 Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F4 Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.